Mechanisms of acute lung injury

Current Opinion in Pulmonary Medicine

Volumn 3, Issue 3, 1997, Pages 234-241

  Downey, Gregory P ^a   Granton, John T ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT RESPIRATORY DISTRESS SYNDROME; HUMAN; LUNG; PATHOPHYSIOLOGY; REVIEW;

HUMANS; LUNG; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 0031136895     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-199705000-00009     Document Type: Article

References (60)

1. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE: Acute respiratory distress in adults. Lancet 1967, 2:319-323.
2. Schuster DP, Kollef MH: Acute respiratory distress syndrome. Dis Mon 1996, 42:270-326.
3. Downey GP, O'Brodovich H: Mechanisms of lung injury and repair. In Textbook of Pediatric Respiratory Medicine, St. Louis: Mosby; 1997, in press.
4. Katzenstein AL, Bloor CM, Leibow AA: Diffuse alveolar damage: the role of oxygen, shock, and related factors: a review. Am J Pathol 1976, 85:209-228.
5. Gattinoni L, Pelosi P, Crotti S, Valenza F: Effects of positive end-expiratory pressure on regional distribution of tidal volume and recruitment in adult respiratory distress syndrome. Am J Respir Crit Care Med 1995, 151:1807-1814.
6. Kawano T, Mori S, Cybulsky M: Effect of granulocyte depletion in a ventilated surfactant-depleted lung. J Appl Physiol 1987, 62:27-33.
7. Takata M, Abe J, Tanaka H, Kitano S, Doi S, Kohsaka T, Miyasaka K: Intraalveolar expression of tumor necrosis factor α gene during conventional and high frequency ventilation [abstract]. Am J Respir Crit Care Med 1996, 153:392.
8. St. John RC, Dorinsky PM: Immunologic therapy for ARDS, septic shock, and multiple organ failure. Chest 1993, 103:932-943.
9. Balk RA, Bone RC: The septic syndrome: definition and clinical implications. Crit Care Clin 1989, 5:1-8.
10. Reynolds HY: Lung inflammation: normal host defense or a complication of some diseases. Ann Rev Med 1987, 38:295-323.
11. Donnelly SC, Strieter RM, Kunkel SL, et al.: Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. Lancet 1993, 341:643-647.
12. Folkesson HG, Matthay MA, Hebert CA, Broaddus VC: Acid aspiration-induced lung injury in rabbits is mediated by interleukin-8-dependent mechanisms. J Clin Invest 1995, 96:107-116.
13. Baughman RP, Gunther KL, Rashkin MC, Keeton DA, Pattishall EN: Changes in the inflammatory response of the lung during acute respiratory distress syndrome: prognostic indicators. Am J Respir Crit Care Med 1996, 154:76-81.
14. Rinaldo JE, Christman JW: Mechanisms and mediators of the adult respiratory distress syndrome. Clin Chest Med 1990, 11:621-632.
15. Kollef MH, Schuster DP: The acute respiratory distress syndrome. N Engl J Med 1995, 332:27-37.
16. Metz C, Sibbald WJ: Anti-inflammatory therapy for acute lung injury: a review of animal and clinical studies. Chest 1991, 100:1110-1119.
17. Downey GP, Fialkow L, Fukushima T: Initial interaction of leukocytes within the microvasculature: deformability, adhesion, and transmigration. New Horiz 1995, 3:219-228.
18. Worthen GS, Schwab BD, Elson EL, Downey GP: Mechanics of stimulated neutrophils: cell stiffening induces retention in capillaries. Science 1989, 245:183-186.
19. Hogg JC, Doerschuk CM: Leukocyte traffic in the lung. Annu Rev Physiol 1995, 57:97-114.
20. Albert RK: Mechanisms of the adult respiratory distress syndrome: selectins. Thorax 1995, 50(suppl 1):S49-S52.
21. Albelda SM, Smith CW, Ward PA: Adhesion molecules and inflammatory injury. Faseb J 1994, 8:504-512.
22. Kuebler WM, Kuhnle GE, Groh J, Goetz AE: Leukocyte kinetics in pulmonary microcirculation: intravital fluorescence microscopic study. J Appl Physiol 1994, 76:65-71.
23. Kuhnle GE, Kuebler WM, Groh J, Goetz AE: Effect of blood flow on the leukocyte-endothelium interaction in pulmonary microvessels. Am J Respir Crit Care Med 1995, 152(4 pt 1):1221-1228.
24. Waddell TK, Fialkow L, Chan CK, Kishimoto TK, Downey GP: Potentiation of the oxidative burst of human neutrophils: a signaling role for L-selectin. J Biol Chem 1994, 269:18485-18491.
25. Vaporciyan AA, DeLisser HM, Van HC, et al.: Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo. Science 1993, 262:1580-1582.
26. Downey G, S. WG, Henson PM, Hyde DM: Neutrophil sequestration and migration in response to local instillation of C5a in the lung: capillary localization and migration across the interalveolar septum. Am Rev Resp Dis 1993, 147:168-176.
27. Ridings PC, Windsor ACJ, Jutila MA, et al.: A dual-binding antibody to E and L-selectin attenuates sepsis-induced lung injury. Am J Respir Crit Care Med 1995, 152:247-253.
28. Goldman G, Welbourn R, Kobzik L, Valeri CR, Shepro D, Hechtman HB: Neutrophil adhesion receptor CD18 mediates remote but not localized acid aspiration injury. Surgery 1995, 117:83-89.
29. 2, increases in lung resistance, wet-to-dry weight ratio, and protein leak.
30. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, and The Methyprednisolone Severe Sepsis Study Group: Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest 1987, 92:1032-1036.
31. Warren HS, Danner RL, Mumford RS: Anti-endotoxin monoclonal antibodies. N Eng J Med 1992, 326:1165-1166.
32. Fisher CJ, Opal SM, Dhainaut JF, Stephens S: Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993, 21:318-337.
33. Fisher CJ Jr, Dhainaut JF, Opal SM, et al.: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial: phase III rhlL-1ra Sepsis Syndrome Study Group. JAMA 1994, 271:1836-1843.
34. Jacobs RF, Tabor DR, Burks AW, Campbell GD: Elevated inteleukin-1 release by human alveolar macrophages during the adult respiratory distress syndrome. Am Rev Repir Dis 1989, 140:1686-1692.
35. Parsons PE, Moore FA, Moore EE, Iklé DN, Henson PM, Worthen GS: Studies on the role of tumor necrosis factor in adult respiratory distress syndrome. Am Rev Respir Dis 1992, 146:694-700.
36. Miller EJ, Cohen AB, Nagao S, et al.: Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality. Am Rev Respir Dis 1992, 146:427-432.
37. Meduri GU, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A: Inflammatory cytokines in the BAL of patients with ARDS: persistent elevation over time predicts poor outcome. Chest 1995, 108:1303-1314.
38. Pugin J, Ricou B, Steinberg KP, Suter PM, Martin TR: Proinflammatory activity in bronchoalveolar lavage fluids from patients with ARDS: a prominent role for interleukin-1. Am J Respir Crit Care Med 1996, 153:1850-1856. This is one of the few studies that has attempted to determine the bioactivity and proinflammatory action of cytokines in BALF in patients with ARDS. A biologic assay was developed to quantify the proinflammatory activity by measuring the level expression of the intracellular adhesion molecule on a culture sample of human epithelial lung adenocarcinoma A549 cell line after incubation with BALF. The relative importance of IL-1 and TNF was also assessed using their respective inhibitors. The proinflammatory activity was compared between normal volunteers, patients with lung masses, patients with ARDS at day 3, patients in their first week after the onset of ARDS, and patients at risk for the development of ARDS. The majority of the proinflammatory activity in BALF was believed to be due to IL-1 and not TNF. This finding emphasized the need to quantify bioactivity of the various cytokines that have been documented to be elevated. Second, proinflammatory activity was maximal on day 3 after the onset of ARDS. Finally, patients at risk for the development of ARDS had high proinflammatory activity in their BALF.
39. Goodman RB, Strieter RM, Martin DP, et al.: Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1996, 154:602-611. This study evaluated the relationship between cytokines and cellularity in BAL fluid of patients with ARDS. Eighty-two patients underwent BAL testing on day 3 and weekly thereafter. Neutrophil chemokines (IL-8 and epithelial cell-derived neutrophil activator-78) monocyte chemokines (MCP-1 and MIP-1), and IL-1β and its inhibitor IL-1RA were measured. Using statistic methods, a fair correlation between concentrations of IL-8 and epithelial cell-derived neutrophil activator-78 and neutrophil levels in BAL fluid was found. BAL fluid was tested in 5 patients and 2 control subjects for PMN chemotactic activity. All ARDS patients had significant chemotactic activity, which was reduced significantly with the addition of an antibody to IL-8.
40. Chollet-Martin S, Jourdain B, Gibert C, Elbim C, Chastre J, Gougerot-Pocidalo MA: Interactions between neutrophils and cytokines in blood and alveolar spaces during ARDS. Am J Respir Crit Care Med 1996, 153:594-601. This study evaluated the level of neutrophil activation by measuring the expression of L-selectin and CD11b in patients with ARDS. the Level of F-actin was also evaluated. In comparison to control subjects (n = 15), patients with ARDS (n = 14) had lower levels of L-selectin and F-actin content and higher levels of CD11b, reflecting a higher degree of neutrophil activation. The level of activation correlated statistically with the degree of lung injury and to the levels of TNF, IL-6, and IL-B.
41. Fukuda Y, Ishizaki M, Masuda Y, Kimura G, Masugi Y: The role of intraalveolar fibrosis in the process of pulmonary structural remodeling in patients with diffuse alveolar damage. Am J Pathol 1987, 126:171-182.
42. Meduri GU, Belenchia JM, Estes RJ, Wunderink RG, El Torky M, Leeper KV: Fibroproliferative phase of ARDS: clinical findings and effects of corticosteroids. Chest 1991, 100:943-952.
43. Collins JF, Smith JD, Coalson JJ, Johanson WFJ: Variability in lung collagen amounts after prolonged support of acute respiratory failure. Chest 1984, 85:641-646.
44. Martin C, Papazian L, Payan M-J, Saux P, Gouin F: Pulmonary fibrosis correlates with outcome in adult respiratory distress syndrome: a study in mechanically ventilated patients. Chest 1995, 107:196-200.
45. Suchyta MR, Clemmer TP, Elliot GC, Orme JF, Weaver LK: The adult respiratory distress syndrome: a report of survival and modifying factors. Chest 1992, 107:1074-1079.
46. Meduri GU, Chinn AJ, Leeper KV: Corticosteroid rescue treatment of progressive fibroproliferation in late ARDS: patterns of response and predictors of outcome. Chest 1994, 105:1516-1527.
47. Murphy G, Docherty AJP: The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 1992, 7:120-125.
48. Ricou B, Nicod L, Lacraz S, Welgus HG, Suter PM, Dayer J-M: Matrix Metalloproteinases and TIMP in Acute Respiratory Distress Syndrome. Am J Resp Crit Care Med 1996, 154:346-352. Early in the course of patients who progressed to ARDS, 92 kD gelatinase was found to be elevated in BALF, and tissue inhibitor of metalloproteinase-1 was found to be elevated in both BALF and plasma in patients with ARDS when compared to controls. Moreover, in patients with prolonged ARDS, the the ratio of 92 kD gelatinase to tissue inhibitor of metalloproteinase remained elevated. Neither the 92 kD gelatinase levels nor tissue inhibitor of metalloproteinase levels in BALF, plasma, or their ratio correlated with clinical indices of the severity of lung injury. However, nonsurvivors had higher levels of 92 kD gelatinase and tissue inhibitor of metalloproteinase as compared with survivors. The elevation of 92 kD gelatinase may reflect the turnover of extracellular matrix proteins in lung injury, and the increased levels of tissue inhibitor of metalloproteinase may interfere with the reparative processes involved in lung remodelling after ARDS.
49. Clark J, Milberg JA, Steinburg KP, Hudson LD: Type III procollagen peptide in the adult respiratory distress syndrome: association of increased peptide levels in bronchoalveolar lavage fluid with increased risk for death. Ann Intern Med 1995, 122:17-23. This important study evaluated a large number of patients (117) at several time points during their ICU stay. It confirmed an earlier study with fewer patients demonstrating elevated levels of type III procollagen peptide in patients with ARDS. Type III procollagen peptide was found to be a reasonable prognostic indicator for mortality, although significant overlap existed between groups. Its main importance stems from the fact that it provides a stimulus for future studies into the pathogenesis of the fibroproliferative response in ARDS.
50. Shapiro SD, Campbell EJ, Kobayashu DK, Welgus HG: Dexamethasone selectively modulates basal and lipopolysaccharide-induced metalloproteinase and tissue inhibitor of metalloproteinase production by human alveolar macrophages. J Immunol 1991, 146:2724-2729.
51. McCartney-Francis NL, Wahl SM: Transforming growth factor β: a matter of life and death. J Leuk Biol 1994, 55:401-409.
52. Khalil N, Corne S, Whitman C, Yacyshyn H: Ptasmin regulates the activation of cell-associated latent TGF-β 1 secreted by rat alveolar macrophages after in vivo bleomycin injury. Am J Respir Cell Mol Biol 1996, 15:252-259.
53. Walmrath D, Gunther A, Ghofrani HA, et al.: Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. Am J Respir Crit Care Med 1996, 154:57-62.
54. Seeger W, Gunther A, Walmrath HD, Grimminger F, Lasch HG: Alveolar surfactant and adult respiratory distress syndrome: pathogenetic role and therapeutic prospects. Clin Invest 1993, 71:177-190.
55. Lewis JF, Veldhuizen R, Possmayer F, et al.: Altered alveolar surfactant is an early marker of acute lung injury in septic adult sheep. Am J Respir Crit Care Med 1994, 150:123-130.
56. Eijking EP, van Daal GJ, Tenbrinck R, et al.: Effect of surfactant replacement on Pneumocystis carinii pneumonia in rats. Intensive Care Med 1991, 17:475-478.
57. Eijking EP, Gommers D, So KL, Vergeer M, Lachmann B: Surfactant treatment of respiratory failure induced by hydrochloric acid aspiration in rats. Anesthesiology 1993, 78:1145-1151.
58. Bone RC: Sepsis and its complications: the clinical problem. Crit Care Med 1994, 22:38-11.
59. Donnelly SC, Strieter RM, Reid PT, et al.: The association between mortality rates and decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with the adult respiratory distress syndrome. Ann Intern Med 1996, 125:191-196. This purpose of this seminal study was to determine the importance of the balance of pro- and anti-inflammatory cytokines in determining mortality in ARDS. In a prospective cohort study, the intra-alveolar concentrations of the proinflammatory cytokines (TNF, IL-1β, and IL-8) and the anti-inflammatory cytokines (IL-10 and IL-1 receptor antagonist) in patients with early ARDS were measured. Concentrations of proinflammatory and anti-inflammatory cytokines within the alveolar air spaces were significantly elevated in patients with ARDS compared with control subjects. Most importantly, a high significant correlation was found between low concentrations of anti-inflammatory cytokines and subsequent patient mortality rates. The authors postulate that failure to mount a localized intrapulmonary anti-inflammatory response early in the course of ARDS contributes to more severe organ injury and worse prognosis and suggest that augmentation of anti-inflammatory cytokine defenses might be a beneficial therapeutic approach to patients with ARDS.
60. Wortel CH, Doerschuk CM: Neutrophils and neutrophil-endothelial cell adhesion in adult respiratory distress syndrome. New Horiz 1993, 1:631-637.